Saturday 17 October 2026
Export NIVF’s income statement to Excel — free account
NewGenIvf Group Limited
NIVF Healthcare Medical Care Facilities
NewGenIvf Group Limited’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 13.0% from fiscal 2024. Dividend growth for five consecutive years; insiders bought in the last twelve months.
0.28
0.03
+12.00%
Follow NIVF
| Dec '17 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Altman Z-Score |
— | — | 2,714,739.26 | — | — | (0.24) |
Altman Z″-Score (non-manufacturers) |
— | — | (0.06) | 4.43 | (2.56) | 3.74 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | (0.31) | 7.78 | 7.81 |
P/Operating CF |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 0.00 | 0.00 | 0.00 | (0.17) |
EV/FCF |
— | — | 0.00 | 0.00 | 0.00 | (0.17) |
Quick Ratio |
— | — | 0.89 | 0.37 | 0.62 | 0.73 |
Current Ratio |
— | — | 0.94 | 2.19 | 1.17 | 3.12 |
Net Debt/EBITDA |
— | — | (0.04) | (0.74) | (1.69) | (0.32) |
Debt/Assets |
0.00% | 0.00% | 0.22% | 0.00% | 65.09% | 12.52% |
Debt/Equity |
— | — | 0.06 | 0.00 | (1.57) | 0.16 |
Asset Turnover |
— | 0.00 | 4.09 | 1.39 | 1.35 | 0.26 |
Operating CF/Net income |
— | — | 3.73 | (13.56) | 15.75 | (1.11) |
Capex/Depreciation |
— | — | (0.94) | (2.24) | (1.00) | (0.56) |
Interest Coverage |
— | — | 5.12 | 0.91 | (1.49) | (17.40) |
| — | — | 0.00% | 7.78% | (59.49%) | 80.63% | |
| — | 0.00% | 31.58% | 3.52% | (13.01%) | 54.43% | |
ROIC |
— | — | 313.44% | 0.83% | (186.26%) | (22.86%) |
Return on Tangible Assets |
— | — | (1,333.43%) | 8.69% | (72.32%) | 145.15% |
Average Days of Receivables |
— | — | 138.40 | 25.85 | 83.37 | 74.18 |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | — | 19.03% | 31.92% | 54.98% | 247.17% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.65 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
— | — | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
— | — | 10.32 | 0.00 | 0.00 | 926.75 |
Operating CF per Share |
— | — | 2.97 | 0.00 | 0.00 | (2,142.37) |
Capex per Share |
— | — | (0.16) | 0.00 | 0.00 | (26.47) |
Free Cash Flow per Share |
— | — | 2.81 | 0.00 | 0.00 | (2,168.84) |
Cash per Share |
— | — | 0.05 | 0.00 | 0.00 | 148.75 |
Shareholders Equity per Share |
— | — | 0.17 | 0.00 | 0.00 | 5,095.43 |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | — | 0.17 | 0.00 | 0.00 | 5,095.43 |
Free Cash Flow |
— | — | 1.62 | (1.84) | (8.32) | (11.06) |
Working Capital |
— | — | (0.16) | 1.34 | 0.45 | 5.02 |
Capital Expenditures |
— | — | (0.09) | (0.07) | (0.05) | (0.13) |
Net Current Asset Value |
— | — | (0.41) | 1.22 | (1.89) | 0.65 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.02 | 0.01 | 0.01 | 0.03 |
| Other line items | ||||||
Depreciation/Fixed assets |
— | — | 0.82 | 0.19 | 0.19 | 0.14 |
Cash ROIC |
— | — | 1,200.00% | (55.64%) | (637.42%) | (35.86%) |
Accounts Receivable Turnover |
— | — | 0.00 | 3.92 | 6.77 | 4.29 |
Accounts Payable Turnover |
— | — | 0.00 | 24.91 | 4.90 | 3.63 |
Inventory Turnover |
— | — | 0.00 | 39.89 | 34.83 | 18.12 |
Average Days of Payables |
— | — | 8.67 | 18.24 | 131.47 | 75.44 |
Days of Inventory on Hand |
— | — | 3.88 | 13.35 | 8.18 | 32.47 |
Average Receivables |
— | — | — | 1.31 | 0.80 | 1.10 |
Average Payables |
— | — | — | 0.14 | 0.74 | 1.04 |
Average Inventory |
— | — | — | 0.09 | 0.10 | 0.21 |
Average Assets |
— | 0.00 | 1.45 | 3.70 | 4.03 | 18.15 |
Average Common Equity |
— | — | — | 1.67 | 0.88 | 12.25 |
Columns are period end dates · fundamentals updated 9 Oct 2026